FDA Approves Aqneursa for the Treatment of Niemann-Pick Disease Type C
September 25, 2024FDA is Alerting Patients and Health Care Professionals About the Voluntary Withdrawal of Oxbryta from the Market Due to Safety Concerns
September 26, 2024September 26, 2024 – Bristol Myers Squibb announced the U.S. Food and Drug Administration (FDA) approved Cobenfy (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults.
- Cobenfy represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating schizophrenia by selectively targeting M 1 and M 4 receptors in the brain without blocking D 2 receptors. Schizophrenia is estimated to impact approximately 2.8 million people in the United States. Symptoms typically first appear in early adulthood and present differently.
- While the current standard of care can be effective in managing symptoms of schizophrenia, up to 60% of people experience inadequate improvement in symptoms or intolerable side effects during therapy, making symptoms difficult to diagnose and manage.
- Source: Bristol Myers Squibb